Plain-English translation of NCT06406634 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a Phase II clinical trial testing (a type of immunotherapy) combined with two other medications— (a targeted therapy pill) and chemotherapy infused directly into the liver—to treat advanced hepatocellular carcinoma (liver cancer) that cannot be surgically removed. Researchers want to see whether this three-part approach works better than existing treatments for people whose cancer has spread too much to be cut out or destroyed with other standard methods.
Currently, treatment options for advanced liver cancer that cannot be surgically removed are limited. This trial exists to test whether combining three different types of treatment—each attacking cancer in a different way—might help more patients survive longer and have better outcomes than treatments used today.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you would receive a combination of three treatments: a chemotherapy infusion delivered directly into your liver through a special catheter, an intravenous immunotherapy drug given every three weeks, and daily pills of a targeted therapy medication. You would have regular clinic visits for blood tests, scans, and physical exams to monitor how your cancer responds and how you're tolerating the treatments. The study expects to enroll about 30 participants and will track your health throughout the treatment period and follow-up visits.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China